ReviewFrontiers in medicine2026
Molecular biomarkers in dialysis-related thrombosis and anticoagulation monitoring: thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, soluble thrombomodulin, tPA/PAI-1/tPAIC, and Anti-Xa.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with end-stage renal disease (ESRD) undergoing renal replacement therapies, including hemodialysis, continuous renal replacement therapy (CRRT), and peritoneal dialysis, face a dual risk of thrombosis and bleeding complications. Conventional coagulation monitoring parameters, such as activated partial thromboplastin time (APTT) and prothrombin time (PT), have substantial limitations in uremic patients and fail to accurately reflect their true hemostatic status. In recent years, emerging molecular biomarkers, including thrombin-antithrombin complex (TAT), plasmin-α2-antiplasmin complex (PIC), soluble thrombomodulin (sTM), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), tPA-PAI-1 complex (tPAIC) and anti-factor Xa activity (Anti-Xa), have been investigated as complementary biomarkers for assessing thrombin generation, fibrinolytic activation, endothelial injury, fibrinolytic dysregulation, and anticoagulant drug effect in selected dialysis-related settings. This review summarizes the biological characteristics of these biomarkers, their clinical utility across different dialysis modalities, recent advances in detection methodologies, and strategies for multimarker monitoring. Current evidence suggests that these biomarkers may provide complementary mechanistic information beyond conventional assays regarding coagulation activation, fibrinolytic status, endothelial injury, and anticoagulant drug effect. However, dialysis-specific outcome evidence remains uneven, and no validated five-marker strategy has yet been established for routine clinical decision-making. Therefore, these biomarkers should currently be viewed as adjunctive and exploratory tools, with potential use in selected scenarios such as CRRT anticoagulation assessment, vascular access risk stratification, and individualized anticoagulant evaluation. However, several challenges remain, including assay standardization, establishment of reference ranges, and cost-effectiveness evaluation. Further prospective studies are needed to validate whether scenario-based single-marker or multimarker interpretation can improve clinically meaningful outcomes, including circuit patency, vascular access survival, bleeding prevention, and individualized anticoagulation management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.